Valion Bio, Inc. Increase Decrease In Operating Lease Liability
Valion Bio, Inc. (VBIO) reported Increase Decrease In Operating Lease Liability of -$242.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-14
- Valion Bio, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$114.00K.
- Valion Bio, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$128.00K.
- Valion Bio, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Valion Bio, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Valion Bio, Inc. increase decrease in operating lease liability for fiscal 2025 was $0.00.
- Valion Bio, Inc. increase decrease in operating lease liability for fiscal 2024 was -$369.00K.
- Valion Bio, Inc. increase decrease in operating lease liability for fiscal 2023 was -$161.00K.
- Valion Bio, Inc. increase decrease in operating lease liability for fiscal 2022 was -$178.00K, a 4550.00% decline from fiscal 2021.
| Period end | Increase Decrease In Operating Lease Liability 1 month | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$242.00K 10-Q · filed 2026-08-14 | -$242.00K derived: sum of 3 quarters · filed 2026-08-14 | -$242.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$128.00K 10-Q · filed 2026-05-14 | -$128.00K derived: sum of 2 quarters · filed 2026-05-14 | -$128.00K derived: sum of 3 quarters · filed 2026-05-14 | -$128.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $0.00 10-K · filed 2026-03-30 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $0.00 10-Q · filed 2025-11-14 | -$273.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | -$273.00K derived: sum of 3 quarters · filed 2026-08-14 | -$290.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | -$273.00K derived: sum of 2 quarters · filed 2026-05-14 | -$290.00K derived: sum of 3 quarters · filed 2026-05-14 | -$321.00K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$290.00K derived: sum of 2 quarters · filed 2026-03-30 | -$321.00K derived: sum of 3 quarters · filed 2026-03-30 | -$369.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$48.00K derived: sum of 2 quarters · filed 2025-11-14 | -$96.00K 10-Q · filed 2025-11-14 | -$142.00K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$79.00K 10-Q · filed 2025-08-14 | -$125.00K derived: sum of 3 quarters · filed 2025-08-14 | -$170.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$48.00K 10-Q · filed 2025-05-15 | -$94.00K derived: sum of 2 quarters · filed 2025-05-15 | -$139.00K derived: sum of 3 quarters · filed 2025-05-15 | -$184.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$91.00K derived: sum of 2 quarters · filed 2025-03-21 | -$136.00K derived: sum of 3 quarters · filed 2025-03-21 | -$161.00K 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$90.00K derived: sum of 2 quarters · filed 2024-11-14 | -$115.00K 10-Q · filed 2024-11-14 | -$158.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$70.00K 10-Q · filed 2024-08-14 | -$113.00K derived: sum of 3 quarters · filed 2024-08-14 | -$171.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$25.00K 10-Q · filed 2024-05-15 | -$68.00K derived: sum of 2 quarters · filed 2024-05-15 | -$126.00K derived: sum of 3 quarters · filed 2024-05-15 | -$167.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$101.00K derived: sum of 2 quarters · filed 2024-03-25 | -$142.00K derived: sum of 3 quarters · filed 2024-03-25 | -$178.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$99.00K derived: sum of 2 quarters · filed 2023-11-14 | -$135.00K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | -$41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$77.00K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$36.00K 10-Q · filed 2023-05-15 | ||||
| 2022-01-31 | -$36.00K 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $4.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |